Konstantin Konstantinov - 16 Aug 2022 Form 4 Insider Report for Codiak BioSciences, Inc.

Role
Chief Technology Officer
Signature
/s/ Yalonda Howze, Attorney-in-Fact for Konstantin Konstantinov
Issuer symbol
N/A
Transactions as of
16 Aug 2022
Net transactions value
-$3,718
Form type
4
Filing time
21 Feb 2023, 15:32:01 UTC
Previous filing
31 May 2022
Next filing
20 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDAKQ Common Stock Options Exercise +4,200 +243% 5,931 16 Aug 2022 Direct F1
transaction CDAKQ Common Stock Sale $2,894 -1,308 -22% $2.21* 4,623 17 Aug 2022 Direct F2
transaction CDAKQ Common Stock Options Exercise +4,200 +91% 8,823 16 Feb 2023 Direct F1
transaction CDAKQ Common Stock Sale $824 -1,391 -16% $0.5922* 7,432 17 Feb 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDAKQ Restricted Stock Units Options Exercise $0 -4,200 -25% $0.000000 12,600 16 Aug 2022 Common Stock 4,200 Direct F3, F4
transaction CDAKQ Restricted Stock Units Options Exercise $0 -4,200 -33% $0.000000 8,400 16 Feb 2023 Common Stock 4,200 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2 The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of RSUs pursuant to a "sell to cover" provision included in the RSU Agreement.
F3 Each RSU represents a contingent right to receive one share of common stock.
F4 On February 16, 2022, the reporting person was granted 16,800 RSUs, vesting in four equal installments every six months beginning on the six month anniversary of the grant date.